ImmunoGen, Inc. IMU.F Stock
ImmunoGen, Inc. Price Chart
ImmunoGen, Inc. IMU.F Financial and Trading Overview
| ImmunoGen, Inc. stock price | 28.74 EUR |
| Previous Close | 16.4 EUR |
| Open | 16.86 EUR |
| Bid | 17.35 EUR x 100000 |
| Ask | 17.6 EUR x 100000 |
| Day's Range | 16.86 - 16.86 EUR |
| 52 Week Range | 3.14 - 16.86 EUR |
| Volume | 90 EUR |
| Avg. Volume | 739 EUR |
| Market Cap | 4.31B EUR |
| Beta (5Y Monthly) | 0.891197 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | 0 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 9.79 EUR |
IMU.F Valuation Measures
| Enterprise Value | 3.56B EUR |
| Trailing P/E | N/A |
| Forward P/E | -21.068748 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 35.782257 |
| Price/Book (mrq) | 31.270872 |
| Enterprise Value/Revenue | 29.527 |
| Enterprise Value/EBITDA | -14.916 |
Trading Information
ImmunoGen, Inc. Stock Price History
| Beta (5Y Monthly) | 0.891197 |
| 52-Week Change | 427.36% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 16.86 EUR |
| 52 Week Low | 3.14 EUR |
| 50-Day Moving Average | 8.91 EUR |
| 200-Day Moving Average | 5.78 EUR |
IMU.F Share Statistics
| Avg. Volume (3 month) | 739 EUR |
| Avg. Daily Volume (10-Days) | 606 EUR |
| Shares Outstanding | 255.97M |
| Float | 190.46M |
| Short Ratio | N/A |
| % Held by Insiders | 0.36% |
| % Held by Institutions | 90.67% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -198.88% |
| Operating Margin (ttm) | -199.40% |
| Gross Margin | -83.71% |
| EBITDA Margin | -197.95% |
Management Effectiveness
| Return on Assets (ttm) | -39.029% |
| Return on Equity (ttm) | -111.95% |
Income Statement
| Revenue (ttm) | 120.57M EUR |
| Revenue Per Share (ttm) | 0.47 EUR |
| Quarterly Revenue Growth (yoy) | 31.00% |
| Gross Profit (ttm) | -104764000 EUR |
| EBITDA | -238676000 EUR |
| Net Income Avi to Common (ttm) | -239798000 EUR |
| Diluted EPS (ttm) | -0.92 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 201.25M EUR |
| Total Cash Per Share (mrq) | 0.89 EUR |
| Total Debt (mrq) | 14.26M EUR |
| Total Debt/Equity (mrq) | 11.7 EUR |
| Current Ratio (mrq) | 2.4 |
| Book Value Per Share (mrq) | 0.539 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -262119008 EUR |
| Levered Free Cash Flow (ttm) | -130357872 EUR |
Profile of ImmunoGen, Inc.
| Country | Germany |
| State | MA |
| City | Waltham |
| Address | 830 Winter Street |
| ZIP | 02451-1477 |
| Phone | 781 895 0600 |
| Website | https://www.immunogen.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 277 |
ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti-FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.
Q&A For ImmunoGen, Inc. Stock
What is a current IMU.F stock price?
ImmunoGen, Inc. IMU.F stock price today per share is 28.74 EUR.
How to purchase ImmunoGen, Inc. stock?
You can buy IMU.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for ImmunoGen, Inc.?
The stock symbol or ticker of ImmunoGen, Inc. is IMU.F.
Which industry does the ImmunoGen, Inc. company belong to?
The ImmunoGen, Inc. industry is Biotechnology.
How many shares does ImmunoGen, Inc. have in circulation?
The max supply of ImmunoGen, Inc. shares is 281.13M.
What is ImmunoGen, Inc. Price to Earnings Ratio (PE Ratio)?
ImmunoGen, Inc. PE Ratio is 0.00000000 now.
What was ImmunoGen, Inc. earnings per share over the trailing 12 months (TTM)?
ImmunoGen, Inc. EPS is 0 EUR over the trailing 12 months.
Which sector does the ImmunoGen, Inc. company belong to?
The ImmunoGen, Inc. sector is Healthcare.